Filana Therapeutics, Inc.: 10-Q filed 2024-08-08
What Filana Therapeutics, Inc. reported in its quarterly report filed 2024-08-08 (fiscal Q2 2024): 32 published measures, 97 facts as tagged in accession 0001437749-24-025611.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2024-08-08
- Fiscal period
- fiscal Q2 2024
- Accession
- 0001437749-24-025611 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Filana Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 243,568,000 | USD | |
| At 2023-12-31 | 151,663,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 188,974,000 | USD | |
| At 2024-03-31 | 78,597,000 | USD | |
| At 2023-12-31 | 137,468,000 | USD | |
| At 2023-06-30 | 179,353,000 | USD | |
| At 2023-03-31 | 204,005,000 | USD | |
| At 2022-12-31 | 227,539,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 207,291,000 | USD | |
| At 2023-12-31 | 121,136,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 6,155,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 31,198,000 | USD | 182 |
| 2024-01-01 to 2024-03-31 | 25,043,000 | USD | 91 |
| 2023-04-01 to 2023-06-30 | -26,376,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -50,647,000 | USD | 181 |
| 2023-01-01 to 2023-03-31 | -24,271,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -37,368,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -33,179,000 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 29,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 351,000 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 123,552,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 953,000 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -29,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -351,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -349,571,000 | USD | |
| At 2023-12-31 | -380,769,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 46,202,000 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 44,601,000 | shares | 182 |
| 2023-04-01 to 2023-06-30 | 41,793,000 | shares | 91 |
| 2023-01-01 to 2023-06-30 | 41,766,000 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 46,202,000 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 45,152,000 | shares | 182 |
| 2023-04-01 to 2023-06-30 | 41,793,000 | shares | 91 |
| 2023-01-01 to 2023-06-30 | 41,766,000 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 0.13 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | 0.7 | USD/shares | 182 |
| 2023-04-01 to 2023-06-30 | -0.63 | USD/shares | 91 |
| 2023-01-01 to 2023-06-30 | -1.21 | USD/shares | 181 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 0.13 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -0.28 | USD/shares | 182 |
| 2023-04-01 to 2023-06-30 | -0.63 | USD/shares | 91 |
| 2023-01-01 to 2023-06-30 | -1.21 | USD/shares | 181 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 0 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 0 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 0 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 0 | USD | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 21,364,000 | USD | |
| At 2023-12-31 | 21,854,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 4,939,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 1,508,000 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -61,402,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -81,336,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -28,777,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -55,289,000 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 222,122,000 | USD | |
| At 2023-12-31 | 129,633,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 54,594,000 | USD | |
| At 2023-12-31 | 14,195,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 82,000 | USD | |
| At 2023-12-31 | 176,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 61,402,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 81,336,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 28,777,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 55,289,000 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 15,198,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 31,431,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 24,969,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 47,089,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 47,976,166 | shares | |
| At 2023-12-31 | 42,236,919 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 538,497,000 | USD | |
| At 2023-12-31 | 518,195,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 24,143,000 | USD | |
| At 2023-12-31 | 24,138,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 2,779,000 | USD | |
| At 2023-12-31 | 2,284,000 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 82,000 | USD | |
| At 2023-12-31 | 176,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 14,831,000 | USD | |
| At 2023-12-31 | 8,497,000 | USD | |
| At 2023-06-30 | 8,497,000 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 46,204,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 49,905,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 3,808,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 8,200,000 | USD | 181 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 244,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 496,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 272,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 544,000 | USD | 181 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 56,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 117,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 119,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 238,000 | USD | 181 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 99,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 259,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 203,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 393,000 | USD | 181 |
Inspect the source
- Entity
- Filana Therapeutics, Inc. / CIK 0001069530
- Captured
- 2026-09-20T05:19:22.728Z
- SEC response SHA-256
98fbf2ec9e4273c7c7ff1d5342c79c5958c86b1e088e060391ccaf7c9ba8ef57
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001069530.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))